Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2061 Target Snapshot

Retinoic acid receptor RXR-alpha · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,495Compounds
676Assays
18Approved Drugs
2,165.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Retinoic acid receptor RXR-alpha shows approved-linked disease relevance led by Constipation. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P19793. Start with Constipation, then reuse UniProt P19793 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Constipation, then reuse UniProt P19793 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
Constipation

Retinoic acid receptor RXR-alpha shows approved-linked disease relevance led by Constipation. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Constipation because it currently carries approved-linked support. Linked drugs include DANTHRON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Retinoic acid receptor RXR-alpha as ChEMBL target CHEMBL2061, mapped to UniProt P19793. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Retinoic acid receptor RXR-alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2061
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P19793
Retinoic acid receptor RXR-alpha
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Retinoic acid receptor RXR-alpha is the right protein anchor across sources, using UniProt P19793 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Constipation is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameRetinoic acid receptor RXR-alpha
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP19793
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRetinoic acid receptor RXR-alpha
UniProt AccessionP19793
Component TypeProtein
Sequence Length462 aa

Retinoic acid receptor RXR-alpha

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Retinoic acid receptor RXR-alpha, mapped to UniProt P19793. Sequence length is 462 aa.

Mapped IDP19793
Review nameRetinoic acid receptor RXR-alpha
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Retinoic acid receptor RXR-alpha shows approved-linked disease relevance led by Constipation. 2 more disease programs remain visible in the same review block.

Approved-linked Approved
Constipation
1 linked drug · 1 direct · 1 efficacy
Linked drugDANTHRON
Clinical signal Phase II
chronic lymphocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugSDX-101
Clinical signal Phase II
multiple myeloma
1 linked drug · 1 direct · 1 efficacy
Linked drugSDX-101
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Constipation because it currently carries approved-linked support. Linked drugs include DANTHRON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseConstipation
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

18
Approved
5
Phase III
5
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC50923.0
KI218.0
EC50821.0
KD203.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL75133 9.7 EC50 0.2 Clinical
CHEMBL38 9.4 Ki 0.4 Approved
CHEMBL75133 9.4 Kd 0.4 Clinical
CHEMBL5289973 9.24 EC50 0.58 Preclinical
CHEMBL5404648 9.15 EC50 0.7 Preclinical
CHEMBL130374 9.1 Ki 0.8 Preclinical
CHEMBL133915 9.1 Ki 0.8 Preclinical
CHEMBL248415 9.05 EC50 0.9 Preclinical
CHEMBL130232 9.0 Ki 1.0 Preclinical
CHEMBL329334 9.0 Ki 1.0 Preclinical
Distribution

pChEMBL Value Distribution

157
5.0
227
5.5
291
6.0
274
6.5
254
7.0
270
7.5
196
8.0
76
8.5
27
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

ALITRETINOIN
CHEMBL705
Approved 1999
Properties Compare Identifier
BEXAROTENE
CHEMBL1023
Approved 1999
Properties Compare Identifier
LEVOTHYROXINE
CHEMBL1624
Approved 1982
Properties Compare Identifier
TRETINOIN
CHEMBL38
Approved 1971
Properties Compare Identifier
Assay Landscape

Assay Landscape

676
Total Assays
1,371
Tested Compounds
2
Assay Types
Binding — 555 assays, 1,371 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 292 923 6.8
single protein format 225 339 6.9
assay format 38 109 6.1
Functional — 121 assays, 222 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 80 191 6.7
assay format 28 31 7.5
organism-based format 13 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine